Phase II study of carboplatin in patients with ovarian carcinoma: a National Cancer Institute of Canada Clinical Trials Group Study.

No abstract is available for this paper.

• Publication year

  1986

• Venue

  Cancer treatment reports

• Publication date

  1986-10-01

• Fields of study

  Medicine

• Identifiers
  PMID 3530446
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• High-dose cisplatin in hypertonic saline in refractory ovarian cancer.

  1985cited by this paper
• Phase I clinical and pharmacologic trial of carboplatin daily for 5 days.

  1984cited by this paper
• Phase I study of carboplatin given on a five-day intravenous schedule.

  1983cited by this paper
• A phase I and pharmacokinetic study of diamminecyclobutane-dicarboxylatoplatinum (NSC 241240).

  1983cited by this paper
• Phase II study of JM8, a new platinum analog, in advanced ovarian carcinoma.

  1983cited by this paper
• USE OF HIGH DOSE CIS‐DICHLORODIAMMINE PLATINUM (II) (NSC—119875) † FOLLOWING FAILURE ON PREVIOUS CHEMOTHERAPY FOR ADVANCED CARCINOMA OF THE OVARY

  1981cited by this paper

• Ionic Ruthenium and Iron Based Complexes Bearing Silver Containing Anions as a Potent New Class of Anticancer Agents

  2021cites this paper
• [dl-1,2-Bis(2-hydroxyphenyl)ethylenediamine]dichloroplatinum(II), a new compound for the therapy of ovarian cancer

  2005cites this paper
• Phase II study of carboplatin in recurrent ovarian cancer: severe hematologic toxicity in previously treated patients

  2004cites this paper
• A dose escalation study of carboplatin and ifosfamide in advanced ovarian cancer

  2004cites this paper
• Cytotoxicity of antitumor platinum complexes withl-buthionine-(R, S)-sulfoximine and/or etanidazole in human carcinoma cell lines sensitive and resistant to cisplatin

  2004cites this paper
• Second-line chemotherapy with gemcitabine and carboplatin in paclitaxel-pretreated, platinum-sensitive ovarian cancer patients. A Hellenic Cooperative Oncology Group Study.

  2004cites this paper
• Combination of etanidazole with cyclophosphamide and platinum complexes

  2004cites this paper
• Prospective study of carboplatin-based chemotherapy for pediatric germ cell tumors.

  2002cites this paper
• Second-line carboplatin and gemcitabine in platinum sensitive ovarian cancer--a dose-finding study by the Arbeitsgemeinschaft Gynäkologische Onkologie (AGO) Ovarian Cancer Study Group.

  2001cites this paper
• Multi-center study of two dose levels of paclitaxel with carboplatin in locally advanced and metastatic non-small cell lung cancer (NSCLC).

  2001cites this paper
• Oxaliplatin or paclitaxel in patients with platinum-pretreated advanced ovarian cancer: A randomized phase II study of the European Organization for Research and Treatment of Cancer Gynecology Group.

  2000cites this paper
• Preclinical Models for High-Dose Therapy

  1997cites this paper
• Treatment of advanced epithelial ovarian cancer: past, present and future.

  1995cites this paper
• Modeling toxicity and response in carboplatin-based combination chemotherapy.

  1994cites this paper
• Oral etoposide is active against platinum-resistant epithelial ovarian cancer.

  1994cites this paper
• Salvage therapy for recurrent and refractory ovarian cancer with high-dose chemotherapy and autologous bone marrow support: a Gynecologic Oncology Group pilot study.

  1994cites this paper
• Comparison of the emetogenic potential between cisplatin and carboplatin in combination with alkylating agents.

  1994cites this paper
• Carboplatin plus ifosfamide as salvage treatment of epithelial ovarian cancer: a pilot study.

  1993cites this paper
• Cisplatin-cyclophosphamide versus carboplatin-cyclophosphamide in advanced ovarian cancer: a randomized phase III study of the National Cancer Institute of Canada Clinical Trials Group.

  1992cites this paper
• Relationships between carboplatin exposure and tumor response and toxicity in patients with ovarian cancer.

  1992cites this paper
• Salvage Carboplatin Therapy for Advanced Ovarian Cancer After First‐Line Treatment with Cisplatin

  1992cites this paper
• Carboplatin in the treatment of carcinoma of the ovary: the National Cancer Institute of Canada experience. Ovarian Cancer Subcommittee.

  1992cites this paper
• Current experience with high-dose carboplatin therapy.

  1992cites this paper
• Utility of individualized carboplatin dosing alone and in combination regimens.

  1992cites this paper
• Cisplatin, carboplatin, and cyclophosphamide combination chemotherapy in advanced-stage ovarian carcinoma: an Eastern Cooperative Oncology Group pilot study.

  1991cites this paper
• Continuous infusion carboplatin on a 21-day schedule: a phase I and pharmacokinetic study.

  1991cites this paper
• A phase II trial of intravenous etoposide (VP-16-213) in epithelial ovarian cancer resistant to cisplatin or carboplatin: clinical and serological evidence of activity

  1991cites this paper
• The ‘failure free interval’ defines the likelihood of resistance to carboplatin in patients with advanced epithelial ovarian cancer previously treated with cisplatin: relevance to therapy and new drug testing

  1991cites this paper
• Carboplatin in childhood brain tumors: A children's cancer study group phase II trial

  1990cites this paper
• A Phase II Trial of Mitomycin in Patients with Epithelial Ovarian Carcinoma Resistant to Cisplatin or Carboplatin

  1990cites this paper
• A phase II trial of carboplatin for recurrent or metastatic squamous carcinoma of the uterine cervix: a Southwest Oncology Group study.

  1990cites this paper
• Crossover study with cisplatin or carboplatin in advanced ovarian cancer.

  1990cites this paper
• Randomized trial in advanced ovarian cancer comparing cisplatin and carboplatin.

  1989cites this paper
• Carboplatin: a clinical review.

  1989cites this paper
• The pharmacology of carboplatin.

  1989cites this paper
• Carboplatin in refractory epithelial ovarian cancer.

  1989cites this paper
• Teniposide in the treatment of small-cell lung cancer: the influence of prior chemotherapy.

  1988cites this paper
• [Organoplatinum compounds. 1987 update].

  1988cites this paper
• Carboplatin: current status and future prospects.

  1988cites this paper
• Carboplatin: A New Cisplatin Analog

  1988cites this paper
• Phase I and II Agents in Cancer Therapy: Two Cisplatin Analogues and High‐Dose Cisplatin in Hypertonic Saline or With Thiosulfate Protection

  1987cites this paper